Literature DB >> 20889980

Mutational analysis reveals a complex interplay of peptide binding and multiple biological features of HLA-B27.

Begoña Galocha1, José A López de Castro.   

Abstract

Molecular polymorphism influences the strong association of HLA-B27 with ankylosing spondylitis through an unknown mechanism. Natural subtypes and site-directed mutants were used to analyze the effect of altering the peptide-binding site of this molecule on its stability, interaction with tapasin, folding, and export. The disease-associated subtypes B*2705, B*2702, and B*2704 showed higher thermostability at 50 °C than all other subtypes and mutants, except some mimicking B*2702 polymorphism. The lowest values were found among pocket B mutants, most of which interacted strongly with tapasin, but otherwise there was no correlation between thermostability and tapasin interaction. Mutants resulting in increased hydrophobicity frequently acquired their maximal thermostability faster than those with increased polarity, suggesting that this process is largely driven by the thermodynamics of peptide binding. Folding, export, and tendency to misfold were influenced by polymorphism all along the peptide-binding site and were not specifically dependent on any particular region or structural feature. Frequent uncoupling of thermostability, folding/misfolding, and export can be explained by the distinct effect of mutations on the acquisition of a folded conformation, the optimization rate of B27-peptide complexes, and their quality control in the endoplasmic reticulum, all of which largely depend on the ways in which mutations alter peptide binding, without excluding additional effects on interactions with tapasin or other proteins involved in folding and export. The similarity of the generally disease-associated B*2707 to nondisease-associated subtypes in all the features analyzed suggests that molecular properties other than antigen presentation may not currently explain the relationship between HLA-B27 polymorphism and ankylosing spondylitis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20889980      PMCID: PMC2998085          DOI: 10.1074/jbc.M110.149906

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  63 in total

1.  Thermal stability comparison of purified empty and peptide-filled forms of a class I MHC molecule.

Authors:  M L Fahnestock; I Tamir; L Narhi; P J Bjorkman
Journal:  Science       Date:  1992-12-04       Impact factor: 47.728

2.  HLA-B44 polymorphisms at position 116 of the heavy chain influence TAP complex binding via an effect on peptide occupancy.

Authors:  Vilasack Thammavongsa; Gayatri Raghuraman; Tracy M Filzen; Kathleen L Collins; Malini Raghavan
Journal:  J Immunol       Date:  2006-09-01       Impact factor: 5.422

Review 3.  Guilt by association: HLA-B27 and ankylosing spondylitis.

Authors:  R Benjamin; P Parham
Journal:  Immunol Today       Date:  1990-04

4.  Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro.

Authors:  T N Schumacher; M T Heemels; J J Neefjes; W M Kast; C J Melief; H L Ploegh
Journal:  Cell       Date:  1990-08-10       Impact factor: 41.582

5.  Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products.

Authors:  N J Stam; H Spits; H L Ploegh
Journal:  J Immunol       Date:  1986-10-01       Impact factor: 5.422

6.  Structure and diversity of HLA-B27-specific T cell epitopes. Analysis with site-directed mutants mimicking HLA-B27 subtype polymorphism.

Authors:  V Calvo; S Rojo; D López; B Galocha; J A López de Castro
Journal:  J Immunol       Date:  1990-05-15       Impact factor: 5.422

7.  The HLA-A,B "negative" mutant cell line C1R expresses a novel HLA-B35 allele, which also has a point mutation in the translation initiation codon.

Authors:  J Zemmour; A M Little; D J Schendel; P Parham
Journal:  J Immunol       Date:  1992-03-15       Impact factor: 5.422

8.  Recognition of HLA-B27 and related antigen by a monoclonal antibody.

Authors:  S A Ellis; C Taylor; A McMichael
Journal:  Hum Immunol       Date:  1982-08       Impact factor: 2.850

9.  Role of binding pockets for amino-terminal peptide residues in HLA-B27 allorecognition.

Authors:  J A Villadangos; B Galocha; D López; V Calvo; J A López de Castro
Journal:  J Immunol       Date:  1992-07-15       Impact factor: 5.422

10.  Natural HLA class I polymorphism controls the pathway of antigen presentation and susceptibility to viral evasion.

Authors:  Danielle Zernich; Anthony W Purcell; Whitney A Macdonald; Lars Kjer-Nielsen; Lauren K Ely; Nihay Laham; Tanya Crockford; Nicole A Mifsud; Mandvi Bharadwaj; Linus Chang; Brian D Tait; Rhonda Holdsworth; Andrew G Brooks; Stephen P Bottomley; Travis Beddoe; Chen Au Peh; Jamie Rossjohn; James McCluskey
Journal:  J Exp Med       Date:  2004-06-28       Impact factor: 14.307

View more
  4 in total

1.  Peptide handling by HLA-B27 subtypes influences their biological behavior, association with ankylosing spondylitis and susceptibility to endoplasmic reticulum aminopeptidase 1 (ERAP1).

Authors:  Noel García-Medel; Alejandro Sanz-Bravo; Carlos Alvarez-Navarro; Patricia Gómez-Molina; Eilon Barnea; Miguel Marcilla; Arie Admon; José A López de Castro
Journal:  Mol Cell Proteomics       Date:  2014-09-03       Impact factor: 5.911

Review 2.  ERAP1 in the pathogenesis of ankylosing spondylitis.

Authors:  Emma Reeves; Tim Elliott; Edward James; Christopher J Edwards
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

3.  Functional interaction of the ankylosing spondylitis-associated endoplasmic reticulum aminopeptidase 1 polymorphism and HLA-B27 in vivo.

Authors:  Noel García-Medel; Alejandro Sanz-Bravo; Dung Van Nguyen; Begoña Galocha; Patricia Gómez-Molina; Adrián Martín-Esteban; Carlos Alvarez-Navarro; José A López de Castro
Journal:  Mol Cell Proteomics       Date:  2012-08-23       Impact factor: 5.911

4.  Ankylosing spondylitis risk factors: a systematic literature review.

Authors:  Mark C Hwang; Lauren Ridley; John D Reveille
Journal:  Clin Rheumatol       Date:  2021-03-22       Impact factor: 3.650

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.